Drug Delivery to the Eye with a Transdermal Therapeutic System.

Isowaki, Akiharu; Ohtori, Akira; Matsuo, Yumi; Tojo, Kakuji

doi:10.1248/bpb.26.69

Cited by 14 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacokinetic parameters obtained from transdermal prednisolone administration in rats have shown that a 3mg/10cm 2 / patch, testing 30cm 2 patches (about 9 mg prednisolone per patch), delivers the same peak plasma concentration as a 10 mg/kg oral dose of prednisolone [57]. The oral formulation peaks in plasma concentration at 1000 ng/mL within the first hour and diminishes to <50 ng/mL within 5 hours.…”

Section: Discussionmentioning

confidence: 99%

Development and In Vitro Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Ramesh¹,

Zamat²,

Vadlamudi³

et al. 2022

J Drug Res Dev

View full text Add to dashboard Cite

Medication nonadherence results in avoidable symptom exacerbations and hospitalization, causing thousands of deaths and billions of dollars in healthcare costs annually. Although pharmacological therapies are present for chronic diseases, lengthy and complicated medication regimens often have high rates of nonadherence. Transdermal drug delivery is a potential method of reducing medication nonadherence as it allows for long-course medication regimens to be simplified to a one-time epidermal patch. We have engineered a transdermal drug delivery system on a customizable platform to longitudinally deliver a wide variety of soluble small-molecule drugs. As a proof of concept, we have chosen to administer long-course corticosteroids for chronic inflammatory disease via epidermal patch. A drug-in-adhesive matrix consisting of the drug, adhesive, solvents, and penetration enhancers, was cured onto a fluoropolymer release liner. The transdermal drug delivery system has an integrated tapering mechanism to avoid end-of-course steroid dependence and can incorporate other small-molecule medications required for cases of polypharmacy. To date, there have been no successful attempts to develop long-term steroid patches for systemic delivery, which may be attributed to issues with patch adhesion and skin irritation over extended periods of time. We have analyzed such challenges and have designed a proof of concept system to overcome these obstacles in order to provide patients with a simple, inexpensive, and effective solution to complicated and long-term treatment regimens.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and In Vitro Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Ramesh¹,

Zamat²,

Vadlamudi³

et al. 2022

J Drug Res Dev

View full text Add to dashboard Cite

show abstract

“…Pharmacokinetic parameters obtained from transdermal prednisolone administration in rats have shown that a 3mg/10cm 2 /patch, testing 30cm 2 patches (about 9mg prednisolone per patch), delivers the same peak plasma concentration as a 10mg/kg oral dose of prednisolone [56]. The oral formulation peaks in plasma concentration at 1000ng/mL within the rst hour and diminishes to <50ng/mL within 5 hours.…”

Section: Discussionmentioning

confidence: 99%

Development and Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Ramesh

Zamat

Vadlamudi

et al. 2021

Preprint

View full text Add to dashboard Cite

Medication nonadherence results in avoidable symptom exacerbations and hospitalization, causing thousands of deaths and billions of dollars in healthcare costs annually. Although pharmacological therapies are present for chronic diseases, lengthy and complicated medication regimens often have high rates of nonadherence. Transdermal drug delivery is a potential method of reducing medication nonadherence as it allows for long-course medication regimens to be simplified to a one-time epidermal patch. We have engineered a transdermal drug delivery system on a customizable platform to longitudinally deliver a wide variety of soluble small-molecule drugs. As a proof of concept, we have chosen to administer long-course corticosteroids for chronic inflammatory disease via epidermal patch. The transdermal drug delivery system has an integrated tapering mechanism to avoid end-of-course steroid dependence and can incorporate other small-molecule medications required for cases of polypharmacy. To date, there have been no successful attempts to develop long-term steroid patches for systemic delivery which can be attributed to issues with patch adhesion and skin irritation over extended periods of time. We have analyzed such challenges and have designed a proof of concept system to overcome these obstacles in order to provide patients with a simple, inexpensive, and effective solution to complicated and long-term treatment regimens.

show abstract

“…Besides, plasma C max⁡ values that were obtained after 10 mg oral prednisolone in rats (863 ng/mL) were higher than the values observed in the present experiment in cats. This is probably due to the lower volume of distribution of the rat [7]. …”

Section: Discussionmentioning

confidence: 99%

Plasma and Ocular Prednisolone Disposition after Oral Treatment in Cats

Solé

Schaiquevich

Marcelo

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Objective. To evaluate the plasma and aqueous humor disposition of prednisolone after oral administration in cats. Methods. Six cats were administered with a single oral dose of prednisolone (10 mg). Blood and aqueous humor samples were serially collected after drug administration. Prednisolone concentrations in plasma and aqueous humor were measured at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, and 5.0 h after administration by a high-performance liquid chromatographic analytical method developed and validated for this purpose. Results. Mean ± standard error (SE) of maximum plasma prednisolone concentration (300.8 ± 67.3 ng/mL) was reached at 1 h after administration. Prednisolone was distributed to the aqueous humor reaching a mean peak concentration of 100.9 ± 25.5 ng/mL at 1.25 h after administration. The mean ± SE systemic and aqueous humor exposure (AUC) was 553.3 ± 120.0 ng∗h/mL and 378.8 ± 64.9 ng∗h/mL, respectively. A high AUCaqueous humor/AUCplasma ratio was observed (0.68 ± 0.13). The mean half-life time of elimination in plasma and aqueous humor was 0.87 ± 0.16 h and 2.25 ± 0.44 h, respectively. Clinical Significance. The observed high ratio between aqueous humor and plasma prednisolone concentrations indicates that extensive penetration of prednisolone to the anterior segment of the eye may occur. This is the first step that contributes to the optimization of the pharmacological therapeutics for the clinical treatment of uveitis.

show abstract

Drug Delivery to the Eye with a Transdermal Therapeutic System.

Cited by 14 publications

References 5 publications

Development and In Vitro Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Development and In Vitro Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Development and Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Plasma and Ocular Prednisolone Disposition after Oral Treatment in Cats

Contact Info

Product

Resources

About